SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The Plex Prime® SARS-CoV-2 Genotyping* product line has rapidly expanded since launching in July, utilising the company’s unique universal substrate approach and patented multiplexing technology. The suite of products can be used independently or combined to support laboratory investigation and monitoring efforts of key SARS-CoV-2 variants of interest or concern.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005006261/en/
PlexPrime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda)1, in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the PlexPrime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrime®P681R Delta reagents. (Photo: Business Wire)
“Rapid screening of positive samples with a PCR-based approach allows laboratories to easily monitor mutations as they circulate” said Dr Charles Cartwright, SpeeDx Senior Vice President of Clinical Affairs. “The individual mutations targeted with our suite of genotyping reagents have been carefully chosen to represent key lineage divergence, thus we are finding that even the latest emerging variants of interest and concern can be targeted for further analysis with our existing portfolio.”
Plex Prime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda)1, in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the Plex Prime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with Plex Prime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the Plex Prime®P681R Delta reagents. Compatible with standard qPCR and liquid handling instrumentation, the Plex Prime® SARS-CoV-2 Genotyping will reduce the costs and manual processes for laboratories currently practicing high-volume sequence analysis.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
*available as Research Use Only reagents not for use in diagnostic procedures
References
- Tracking SARS-CoV-2 variants. World Health Organisation. Found at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005006261/en/
Contact information
Madeline O’Donoghue - SpeeDx Global Marketing Director
madelineo@speedx.com.au
+61 406 582 808
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces Normal Course Issuer Bid6.11.2025 00:00:00 EET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 12, 2025 and ending November 11, 2026, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,403,042 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 31, 2025. As of the close of business on October 31, 2025, the Company had 28,060,844 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased p
Hyper ® Wins Dual CES 2026 Innovation Awards ® for its Breakthrough Tech Accessories5.11.2025 23:50:00 EET | Press release
Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/ CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed. The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories. “For 20 years, Hyper has led the tech accessory space with industry-defining ‘world’s firsts’ in power, connectivity, mobility, and desktop solutions,” said Gabi Iorio, Director of Global Marketing
CWAN Reports 800+ AI Agents Now Available for Deployment Across $10 Trillion in Client Assets5.11.2025 23:15:00 EET | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced the global deployment of CWAN GenAI, a newly-launched, embedded generative AI platform that can be deployed to transform investment management, risk management, reporting and operations across more than $10 trillion in institutional assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105092732/en/ What sets CWAN GenAI apart from the experimental AI tools flooding the market is its production-ready integration. Unlike copilots or chat tools layered onto legacy systems, CWAN GenAI is fully integrated and deployed into production on CWAN’s front-to-back platform, enabling clients to work alongside AI as collaborative partners in their investment operations. The platform currently supports 800+ AI agents created by CWAN clients and internal teams, plus 20 highly trained domain-specific agents. These agen
IonQ and Swiss Consortium Launch First Citywide Dedicated Quantum Network in Geneva5.11.2025 23:04:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, with luminary Swiss partners, successfully deployed a citywide quantum network in Geneva, Switzerland. This consortium of world-class academic, enterprise, and public institutions will advance quantum cybersecurity and communications research, collaboration, and innovation. The new infrastructure, named the Geneva Quantum Network (GQN), is the nation’s first dedicated quantum network connecting key institutions across the region. “Our involvement in the GQN alongside globally-renowned companies such as Rolex and research leaders like CERN, underscores our IP and pioneering leadership in quantum cybersecurity and communication,” said Niccolo de Masi, Chairman and CEO of IonQ. “IonQ is leveraging existing fiber optic infrastructure to link partners across the Geneva region. Our partnership with leading universities, government, and industry players in Geneva is enabling real-world quantum communications, accelerating research, and b
PPG sets paint stirring world record at SEMA 2025 to highlight benefits of new automated system for body shops5.11.2025 20:41:00 EET | Press release
PPG (NYSE: PPG) today announced that it achieved a GUINNESS WORLD RECORDS™ title for the largest simultaneous paint stirring challenge during a customer event at the 2025 SEMA Show in Las Vegas. More than 275 participants stirred paint together to highlight the manual effort still common in collision repair before PPG unveiled its new SEM MIX’N’SHAKE™ automated stirring solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105923792/en/ More than 275 participants simultaneously stirred paint at SEMA 2025 as PPG breaks the GUINNESS WORLD RECORDS™ title for the largest paint stirring challenge as it unveiled the SEM Mix’n’Shake™ automated stirring system. The SEM Mix’n’Shake system produces a fully homogenized car paint mix in less than 60 seconds. By automating this step, body shops can reduce rework and recover up to 6% more productive work hours annually. The system also improves paint consistency, efficiency and work
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom